Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)

June 6, 2012 by  
Filed under Prostate Cancer News

A Clinical trial that is in phase 2 indicates that Cabozantinib, a medication designed to treat advanced prostate cancer is still showing durable effects on metastatic castration-Resistant prostate Cancer and bone tissue problems experienced by patients.

At the ongoing American Society of Clinical Oncology meeting taking place in Chicago, a data was presented in the Oral session. The use of Cabozantinib for advanced prostate cancer treatment has been compelling and it covers a wider symptoms.

Here  is an online report on this the use of this drug to treat men whose prostate cancer has affected the bones and nearby tissues:

Decreased Circulating Tumor Cells and Bone Biomarkers Also Seen

Exelixis, Inc. EXEL +6.22% today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. These data confirm cabozantinib’s effects on metastatic bone lesions and soft tissue disease, and demonstrate a positive impact on bone related pain and narcotic use, as well as biomarkers of bone formation and resorption. Matthew R. Smith, M.D., Ph.D., Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center and an investigator on the trial, presented the data today in an oral session at the American Society of Clinical Oncology 2012 Annual Meeting (Abstract #4513), which is taking place in Chicago, Illinois. In addition, preliminary results from an ongoing phase 1 investigator-sponsored trial (IST) designed to determine the lowest effective dose of cabozantinib for the treatment of men with CRPC and bone metastases were also presented at the conference. Richard J. Lee, M.D., Ph.D., Assistant Physician in the Department of Medicine at Massachusetts General Hospital Cancer Center, and an investigator on the study, presented the data yesterday in a poster discussion session (Abstract #4566).

Both presentations are available at http://www.exelixis.com/resources/events/asco-2012 .

Cabozantinib in Chemotherapy-Pretreated Metastatic CRPC: Interim Results from a Phase 2 Non-Randomized Expansion Cohort

The interim results reported today include data from 93 men enrolled in the ongoing non-randomized expansion (NRE) 100 mg cohort of the company’s phase 2 randomized discontinuation trial. All patients had bone metastases on bone scan and 46% had measurable soft tissue disease. All patients had received prior docetaxel, 35% had prior abiraterone or MDV3100, and 24% had received prior cabazitaxel. Bone directed therapies such as zoledronic acid, denosumab and alpharadin were used in 57%, 14% and 1% of patients, respectively. Seventy-three percent of patients had received at least 2 prior lines of therapy for CRPC. Clinically significant pain, defined as baseline pain score by Brief Pain Inventory (BPI) greater-than or equal to 4, was present in 44% of patients, with the majority requiring chronic narcotic administration. Click here to read the full extract.

Cabozantinib is a drug that has been associated with the treatment of metastatic prostate cancer. It really showed durable effects in dealing with bone metastases in cancer of the prostate. The clinical trials using this therapy has shown that it inhibits MET and VEGFR2. It also kills tumor cells that block pathways in the body.

This molecular therapy may serve as the ideal future treatment for any kind of metastatic prostate cancer. The above online extract is quite revealing about the effectiveness of this treatment of cancer of the prostate.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)


  1. Treating Metastatic Prostate Cancer To The Bone
  2. Management of Castration-Resistant Prostate Cancer
  3. The Efficacy of Capesaris to Be Tested On Advanced Prostate Cancer
  4. Rising Psa In Metastatic Prostate Cancer
  5. Symptoms Of Metastatic Prostate Cancer – How To Identify Them
  6. Symptoms Metastatic Prostate Cancer To The Lung
  7. Most People Are Not Fully Aware Of Metastatic Prostate Cancer
  8. Metastatic Prostate Cancer Treatment – How It Works
  9. Symptoms Metastatic Prostate Cancer To Lung
  10. Metastatic Prostrate Cancer And Brain Tumor – Learn More
  11. Metastatic Prostate Cancer and Smoking
  12. Later Stages of Prostrate Cancer – Metastatic Prostate Cancer
  13. Chemotherapy Prostrate Cancer for Hormone Refractory Metastatic
  14. Efficacy Of Hormonal Treatment In Prostate Cancer
  15. Metastatic Prostate Cancer To The Bone – The Different Treatments Available

Speak Your Mind

Tell us what you're thinking... !

s